BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Suga T, Sato K, Ohyama T, Matsui S, Kobayashi T, Tojima H, Horiguchi N, Yamazaki Y, Kakizaki S, Nishikido A, Okamura T, Yamada M, Kitamura T, Uraoka T. Ipragliflozin-induced improvement of liver steatosis in obese mice may involve sirtuin signaling. World J Hepatol 2020; 12(7): 350-362 [PMID: 32821334 DOI: 10.4254/wjh.v12.i7.350]
URL: https://www.wjgnet.com/1948-5182/full/v12/i7/350.htm
Number Citing Articles
1
João Victor Salgado, Miguel Angelo Goes, Natalino Salgado Filho. FGF21 and Chronic Kidney DiseaseMetabolism 2021; 118: 154738 doi: 10.1016/j.metabol.2021.154738
2
Omar Hegazi, Samer Alalalmeh, Moyad Shahwan, Ammar Jairoun, Mansour Alourfi, Ghfran Bokhari, Abdullah Alkhattabi, Saeed Alsharif, Mohannad Aljehani, Abdulmalik Alsabban, Mohammad Almtrafi, Ysear Zakri, Abdullah AlMahmoud, Khalid Alghamdi, Ahmed Ashour, Nasser Alorfi. Exploring Promising Therapies for Non-Alcoholic Fatty Liver Disease: A ClinicalTrials.gov AnalysisDiabetes, Metabolic Syndrome and Obesity 2024; : 545 doi: 10.2147/DMSO.S448476
3
Zhicheng Gao, Jiaqi Bao, Yilan Hu, Junjie Tu, Lifang Ye, Lihong Wang. Sodium-glucose Cotransporter 2 Inhibitors and Pathological Myocardial HypertrophyCurrent Drug Targets 2023; 24(13): 1009 doi: 10.2174/1389450124666230907115831
4
Nitin J. Deshmukh, M. S. Kalshetti, Mohan Patil, Pankaj Autade, Ganesh V. Sangle. Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon‐like peptide 1Clinical and Experimental Pharmacology and Physiology 2024; 51(5) doi: 10.1111/1440-1681.13854
5
Claudia Theys, Dorien Lauwers, Claudina Perez-Novo, Wim Vanden Berghe. PPARα in the Epigenetic Driver Seat of NAFLD: New Therapeutic Opportunities for Epigenetic Drugs?Biomedicines 2022; 10(12): 3041 doi: 10.3390/biomedicines10123041
6
Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, Ele Ferrannini, Michael A. Nauck, Soo Lim. SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver diseaseTrends in Endocrinology & Metabolism 2022; 33(6): 424 doi: 10.1016/j.tem.2022.03.005
7
Milton Packer. Differential Pathophysiological Mechanisms in Heart Failure With a Reduced or Preserved Ejection Fraction in DiabetesJACC: Heart Failure 2021; 9(8): 535 doi: 10.1016/j.jchf.2021.05.019
8
Milton Packer. Critical Reanalysis of the Mechanisms Underlying the Cardiorenal Benefits of SGLT2 Inhibitors and Reaffirmation of the Nutrient Deprivation Signaling/Autophagy HypothesisCirculation 2022; 146(18): 1383 doi: 10.1161/CIRCULATIONAHA.122.061732
9
Nunzia D'Onofrio, Celestino Sardu, Maria Consiglia Trotta, Lucia Scisciola, Fabrizio Turriziani, Franca Ferraraccio, Iacopo Panarese, Lella Petrella, Mara Fanelli, Piero Modugno, Massimo Massetti, Ludovica Vittoria Marfella, Ferdinando Carlo Sasso, Maria Rosaria Rizzo, Michelangela Barbieri, Fulvio Furbatto, Fabio Minicucci, Ciro Mauro, Massimo Federici, Maria Luisa Balestrieri, Giuseppe Paolisso, Raffaele Marfella. Sodium-glucose co-transporter2 expression and inflammatory activity in diabetic atherosclerotic plaques: Effects of sodium-glucose co-transporter2 inhibitor treatmentMolecular Metabolism 2021; 54: 101337 doi: 10.1016/j.molmet.2021.101337